A study on breast cancer cell lines and animal models revealed that PARP inhibitors upregulated PD-L1 by inactivating GSK3β, and the combination of PARP inhibitors and anti-PD-L1 demonstrated better therapeutic benefit than each treatment alone (8). Here, PARP1 is linked to breast cancer.